# BerGenBio ASA

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bergenbio-asa

- Industry: Pharmaceuticals
- Headquarters: Bergen, Norway
- Website: www.bergenbio.com
- Total disclosed funding: $8.8M
- Latest round: Series A (Jan 4, 2012)
- Investors on record: 2

## About

BerGenBio ASA is a biopharmaceutical company focused on developing innovative AXL inhibitors to treat aggressive diseases, particularly various cancers and severe respiratory infections.Founded in 2007 and headquartered in Bergen, Norway, BerGenBio ASA specializes in the development of first-in-class AXL inhibitors. The company's notable global presence includes operations aimed at addressing treatments for cancer and severe respiratory infections. CEO Martin Olin leads the firm, which has executed a total of 7 deals. On October 25, 2022, BerGenBio raised NOK 100 million in VENTURE DEBT funding from Meteva, contributing to an overall funding total of NOK 212 million.BerGenBio develops first-in-class AXL inhibitors targeting aggressive diseases, focusing primarily on cancer and severe respiratory infections. Their main product, BEMCENTINIB, inhibits the AXL receptor tyrosine kinase, essential in cancer progression and immune evasion. Currently undergoing clinical trials for indications such as non-small cell lung cancer (NSCLC) and acute myeloid leukemia (AML), the company's offerings cater to oncologists and healthcare providers across Europe and North America.In the most recent financial year, 2022, BerGenBio reported a revenue of NOK 40,616.10 mn, with an EBITDA of NOK -31,819.62 mn, reflecting the challenges and investments typical in biopharmaceutical development.BerGenBio ASA plans to leverage the NOK 100 million raised in VENTURE DEBT funding from October 2022 to support its platform visions and further product development. The company is focused on advancing its flagship product, BEMCENTINIB, and expanding its market reach into new geographic regions, specifically targeting additional markets in Europe and North America by 2024.

## Funding rounds

- Series A, Jan 4, 2012, $8.8M — Sarsia, Investinor

## Investors

- Sarsia (https://capitalatlas.ai/funds/sarsia) — Series A
- Investinor (https://capitalatlas.ai/funds/investinor) — Series A